InsiderTrades

Form 4 for FDMT 4D Molecular Therapeutics, Inc.

Accepted 2023-04-25 00:00:00 ET · period of report 2023-04-21 · accession 0001140361-23-020316 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2023-04-25 2023-04-21 FDMT Bizily Scott Chief Legal, HR Off S - Sale+OE $20.00 -3,750 2,109 -64% -$75.0K
DT 2023-04-25 2023-04-21 FDMT Bizily Scott Chief Legal, HR Off M - OptEx $8.04 +3,750 5,859 +178% +$30.1K
DT 2023-04-25 2023-04-21 FDMT Bizily Scott Chief Legal, HR Off M - OptEx $0.00 -3,750 52.5K -7% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-04-21 S D 3,750 $20.00 2,109 D — —
2 Common Common Stock 2023-04-21 M A 3,750 $8.04 5,859 D — —
3 Derivative Stock Option (Right to Buy) 2023-04-21 M D 3,750 $0.00 52,500 D $8.04 · — to 2032-08-31 3,750 Common Stock (F2) The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.